Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Clinical trials
3,131 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT03119064 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma(329) | terminated | Phase 1 / Phase 2 | 12 | Brown UniversityOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT01301430 | Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.(ParvOryx01) | completed | Phase 1 / Phase 2 | 18 | Oryx GmbH & Co. KGINDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | terminated | Phase 1 | 7 | Samus Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT01865162 | Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study(KGDinGBM) | completed | Phase 1 | 6 | Mid-Atlantic Epilepsy and Sleep Center, LLCOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | withdrawn | Phase 1 / Phase 2 | 0 | Oblato, Inc.INDUSTRY | 0 | Oct 7, 2022 | clinicaltrials |
| NCT05569434 | 68Ga-P16-093 PET/CT Imaging in Glioma Patients | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT00687765 | Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 126 | SanofiINDUSTRY | 1 | Sep 14, 2022 | clinicaltrials |
| NCT03744026 | Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9(SC9-GBM-01) | completed | Phase 1 / Phase 2 | 38 | CarTheraINDUSTRY | 2 | Sep 7, 2022 | clinicaltrials |
| NCT04658836 | Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF | completed | Phase 1 | 21 | Medical University of ViennaOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04200066 | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | University of RochesterOTHER | 0 | Aug 22, 2022 | clinicaltrials |
| NCT03722342 | TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma | unknown | Phase 1 | 9 | PharmAbcineINDUSTRY | 1 | Aug 17, 2022 | clinicaltrials |
| NCT02285959 | Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme | unknown | Phase 1 | 30 | Global Neurosciences InstituteOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM(CYNK001GBM01) | terminated | Phase 1 | 3 | Celularity IncorporatedINDUSTRY | 1 | Aug 10, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT01808820 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | completed | Phase 1 | 20 | Macarena De La Fuente, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT02644291 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | completed | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens(PERFORMANCE) | terminated | Phase 1 | 27 | Eric Thompson, M.D.OTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT02330562 | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | completed | Phase 1 / Phase 2 | 121 | CelgeneINDUSTRY | 2 | Jun 8, 2022 | clinicaltrials |
| NCT01434602 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02709616 | Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)(PERCELLVAC) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT02808364 | Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)(PerCellVac2) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02871843 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas(G-FORCE-1) | completed | Phase 1 | 19 | EpicentRx, Inc.INDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT02415153 | Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02750891 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | completed | Phase 1 / Phase 2 | 18 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01904123 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | completed | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT00303849 | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | completed | Phase 1 / Phase 2 | 33 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT01891747 | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | completed | Phase 1 | 14 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02270034 | Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02526017 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers(FPA008-003) | completed | Phase 1 | 313 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03566199 | MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma(PNOC015) | completed | Phase 1 / Phase 2 | 7 | Sabine Mueller, MD, PhDOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT00867178 | Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2022 | clinicaltrials |
| NCT03341806 | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | completed | Phase 1 | 13 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT01222754 | Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2022 | clinicaltrials |
| NCT03990285 | [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )(Axumin) | completed | Phase 1 | 30 | Ali NabavizadehOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT02010606 | Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | completed | Phase 1 | 39 | Cedars-Sinai Medical CenterOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT05108012 | Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients | unknown | Phase 1 | 5 | Royan InstituteOTHER_GOV | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03374943 | A Trial of KB004 in Patients With Glioblastoma | completed | Phase 1 | 12 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Nov 4, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 13, 2022source: clinicaltrials